Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;36(5):923-925.
doi: 10.1681/ASN.0000000654. Epub 2025 Feb 5.

Effects of Clazakizumab on Anemia and Iron Metabolism in Patients with Kidney Failure

Collaborators, Affiliations

Effects of Clazakizumab on Anemia and Iron Metabolism in Patients with Kidney Failure

Brendon L Neuen et al. J Am Soc Nephrol. .
No abstract available

Keywords: anemia; chronic hemodialysis; chronic inflammation; hemodialysis.

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/F67.

References

    1. Chertow GM Chang AM Felker GM, et al. . IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nat Med. 2024;30(8):2328–2336. doi:10.1038/s41591-024-03043-1 - DOI - PMC - PubMed
    1. Pergola PE Devalaraja M Fishbane S, et al. . Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol. 2021;32(1):211–222. doi:10.1681/ASN.2020050595 - DOI - PMC - PubMed
    1. Pergola PE Davidson M Jensen C, et al. . Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3–5: an analysis of a randomized trial (RESCUE). J Am Soc Nephrol. 2024;35(1):74–84. doi:10.1681/ASN.0000000000000245 - DOI - PMC - PubMed

LinkOut - more resources